Background and Purpose-Predictors of progression of intracranial atherosclerotic stenosis have not been clearly identified. We investigated whether poststroke changes in lipid profiles would affect the prognosis of symptomatic intracranial atherosclerotic stenosis. Methods-This is a substudy of Trial of cilOstazol in Symptomatic intracranial Stenosis 2 (TOSS-2). From 10 centers we enrolled 230 subjects with acute symptomatic stenosis in the M1 segment of the middle cerebral artery or basilar artery. At baseline and 7 months after stroke, subjects underwent MR angiogram and assessment of cardiovascular risk factors including lipoprotein levels. Progression of intracranial atherosclerotic stenosis was determined by comparing stenosis on the baseline and follow-up MR angiograms. Results-Cilostazol treatment was more frequently seen in the nonprogression group (109 of 198 [55.1%]) than in the progression group (11 of 32 [34.4%]). At 7 months after stroke when compared with baseline, low-density lipoprotein cholesterol and total cholesterol levels decreased in both groups. However, only nonprogressors showed increase in high-density lipoprotein cholesterol levels between baseline and follow-up. Changes in apolipoprotein B/apolipoprotein A-I levels were not different between the groups, although apolipoprotein B/A-I at 7 months was higher in progressors than in nonprogressors. Remnant lipoprotein cholesterol levels decreased in nonprogressors, whereas they did not change in progressors. In multivariable analyses, after adjusting for cilostazol treatment and remnant lipoprotein cholesterol reduction or apolipoprotein B/A-I at 7 months, high-density lipoprotein cholesterol elevation remained as a significant predictor for the nonprogression. showed that elevated blood pressure and total cholesterol levels in symptomatic patients with intracranial atherosclerotic stenosis (ICAS) were associated with an increased risk of stroke, myocardial infarction, or vascular death. 2 We Received February 8, 2012; accepted February 23, 2012. 
H yperlipidemia is an established risk factor for extracranial atherosclerosis. However, its role in intracranial atherosclerosis is not clear. 1 A substudy of the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial showed that elevated blood pressure and total cholesterol levels in symptomatic patients with intracranial atherosclerotic stenosis (ICAS) were associated with an increased risk of stroke, myocardial infarction, or vascular death. 2 We recently reported that a higher low-density lipoprotein cholesterol (LDL-C) level in the acute period after ischemic stroke failed to indicate an increased risk of ICAS, whereas an increased apolipoprotein B (apoB)/apolipoprotein A-I (apoAI) ratio was an independent risk factor for ICAS. 3 Thus, we reasoned that poststroke changes in apoB/AI ratio or apoAI-containing high-density lipoprotein cholesterol (HDL-C) may affect the progression of ICAS, a major cause of stroke.
Remnant lipoproteins are products of partially catabolized chylomicrons and very low-density lipoprotein, from which some triglycerides have been removed. These particles are smaller and denser than the parent particles and play a greater role in coronary heart disease risk than their precursors. 4 -8 The Food and Drug Administration of the United States recognized a high remnant lipoprotein cholesterol (RLP-C) level as a coronary heart disease risk factor in 2000. 9 Thereafter, it was reported that high levels of remnant lipoproteins predicted ischemic stroke in a subgroup of patients, who were admitted for cardiac catheterization for chest pain or electrocardiographic ischemic changes, with metabolic syndrome and mild carotid atherosclerosis. 10 In a single-center cross-sectional study, in which RLP-C was measured once during an acute period of stroke, we found an association between elevated levels of RLP-C and large artery atherosclerotic stroke. 11 These findings led us to hypothesize that changes in RLP-C levels may affect the progression of ICAS.
In an investigator-initiated double-blind multicenter randomized trial, the Trial of cilOstazol in Symptomatic intracranial Stenosis 2 (TOSS-2), with 7-month follow-up, we did not observe a significant difference in preventing progression of ICAS and new ischemic lesions between the aspirin plus cilostazol versus aspirin plus clopidogrel. 12 In the study, symptomatic ICAS was defined as a significant focal stenosis in the M1 segment of the middle cerebral artery or basilar artery on MR angiography (MRA) relevant to acute lesions of the index stroke identified by diffusion-weighted MRI. As a substudy of the multicenter trial, we investigated whether changes in lipid profiles would be associated with the angiographic progression of symptomatic ICAS.
Methods

Study Design and Participants
This study was designed a priori as a substudy of the TOSS-2 study, which recruited 457 acute ischemic stroke patients aged Ն35 years with symptomatic ICAS within 2 weeks of symptom onset. Further details of the TOSS-2 study design and methods have been published previously. 12 Among 20 centers, 10 Korean centers that are located in Seoul and surrounding areas participated in this substudy, which recruited 239 subjects who provided written informed consent and whose lipid profiles (total cholesterol, HDL-C, LDL-C, and RLP-C) and MRAs were available. The protocol was approved by the ethics committees of all participating centers. After excluding 9 subjects without follow-up lipid profiles (nϭ8) or MRA (nϭ1) at 7 months, a total of 230 subjects was analyzed.
Procedures
At baseline, subjects underwent MRI including diffusion-weighted MRI, 3-dimensional time-of-flight MRA for intracranial vessels, and 3-dimensional contrast-enhanced MRA for extracranial evaluation.
Follow-up visits with strict monitoring were scheduled at 1, 3, 5, and 7 months. High-sensitivity C-reactive protein levels, glycosylated hemoglobin, and fasting lipid levels including RLP-C levels were measured at the initial and final visits. RLP-C levels in plasma samples that had been stored at Ϫ70°C were measured as previously reported 11, 13 in triplicate after isolation by using an immunoaffinity gel containing monoclonal antibodies to human apoB-100 and apoAI (Jimro-II RLP-C kit, Otsuka, Japan). Mean values were used for the study.
To evaluate the progression of ICAS and occurrence of new ischemic lesions, follow-up MRA and fluid attenuation inversion recovery MR images were obtained at the 7-month follow-up visit or at the time of patient withdrawal. The severity of stenosis for the middle cerebral arteries and basilar artery in each patient was classified by 3 investigators, blinded to clinical information and the location of the symptomatic stenosis, into 1 of 5 grades: normal, mild (signal reduction Ͻ50%), moderate (signal reduction Ն50%), severe (focal signal loss with the presence of distal flow), and occlusion (sudden cutoff without distal flow void). Progression was defined as worsening in the degree of stenosis by 1 grade or more on the follow-up MRA in comparison with the baseline MRA (online-only Data Supplement Figure I ; http://stroke.ahajournals.org). 12 
Statistical Analysis
Data are presented as meanϮSD. Comparisons of continuous variables between groups were performed using t tests. Chi-square test was used to compare proportions between groups. To determine if HDL-C elevation or RLP-C reduction was independently associated with progression versus nonprogression of symptomatic ICAS, multivariable logistic regression analyses were performed, in which those variables with a probability value Ͻ0.05 on univariable analysis were included. All statistical analyses were conducted using the SPSS software package (SPSS 18.0, Chicago, IL). A value of PϽ0.05 was considered statistically significant. Table 1 and online-only Data Supplement Tables I and II summarize demographic and clinical features of the study subjects. Compared with the nonparticipating subgroup of the TOSS-2 subjects, the study subgroup had lower National Institutes of Health Stroke Scale scores, lower rates of nonfatal stroke and major hemorrhagic complications, and higher rate of new ischemic lesions on follow-up MRI during the 7 months follow-up (online-only Data Supplement Tables  I and II ). In addition, the study subgroup had lower rates of smoking history and hyperlipidemia than the nonparticipating subgroup. The rates of cilostazol, clopidogrel, or statin medication did not differ between the subgroups. In the study subgroup, however, the use of angiotensin-converting enzyme inhibitor was less frequent, and the use of angiotensin receptor blocker, calcium channel blocker, or other antihypertensive agents was more frequent than in the nonparticipating subgroup. The other variables including location and severity of symptomatic middle cerebral artery or basilar artery stenosis at baseline also did not differ (online-only Data Supplement Tables I and II) .
Results
Patient Characteristics
Univariable Analysis Showed That Poststroke HDL-C Elevation and RLP-C Reduction Were Associated With the Prevention of ICAS Progression
As shown in Table 1 , the mean age of the progression group (nϭ32, 62.4Ϯ11.3 years) was nonsignificantly lower than
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that of the nonprogression group (nϭ198, 65.3Ϯ10.8; Pϭ0.16). Cilostazol treatment was more frequent in the nonprogression group than in the progression group. In addition, calcium channel blocker medication tended to be more frequent in the nonprogression group than in the progression group (Pϭ0.08). At 7 months, diastolic blood pressure was nonsignificantly lower in the nonprogression group than in the progression group (Pϭ0.12). Glycosylated hemoglobin and high-sensitivity C-reactive protein did not differ between the groups either at baseline or at 7 months (Table 1) . At 7 months after stroke when compared with the baseline lipid profiles (Table 2) , LDL-C ( Figure 1A ) and total cholesterol levels decreased in both groups. However, only nonpro- gressors showed an increase in HDL-C levels ( Figure 1B ) between the baseline and follow-up. Thus, unlike LDL-C levels at 7 months ( Figure 1C ), HDL-C levels at 7 months were lower in the progression group than in the nonprogression group ( Figure 1D ). During the treatment period, changes in apoB/AI levels were not different between the 2 groups (Figure 2A ), although apoB/AI at 7 months was higher in progressors than in nonprogressors ( Figure 2B ). The rate of statin medication did not differ between the groups. Baseline RLP-C levels were not different between progressors and nonprogressors (Pϭ0.19). At 7 months after stroke compared with the baseline values, RLP-C levels decreased in nonprogressors (PϽ0.001), whereas they did not change in progressors (Pϭ0.80; Figure 2C ). Thus, RLP-C levels at 7 months tended to be higher in progressors than in nonprogressors (Pϭ0.10; Figure 2D ).
In subjects treated with cilostazol (nϭ120), RLP-C levels decreased significantly at 7 months after stroke (6.3Ϯ6.8 mg/dL) compared with the baseline values (8.0Ϯ5.8 mg/dL; PϽ0.001). However, in subjects treated with clopidogrel (nϭ110), RLP-C did not change: 7.4Ϯ4.9 mg/dL at baseline and 7.5Ϯ5.8 mg/dL at 7 months (Pϭ0.92). Unlike in the levels of RLP-C, HDL-C levels were increased and apoB/AI ratios were decreased regardless of the cilostazol or clopidogrel treatment (online-only Data Supplement Figure II) .
Multivariable Analysis Showed That Poststroke HDL-C Elevation Was Independently Associated With the Prevention of ICAS Progression
Logistic regression analyses were conducted, in which variables with a probability value Ͻ0.05 in the univariable analyses were included. After adjusting for cilostazol treatment and RLP-C reduction, HDL-C elevation remained as significant predictors for the nonprogression versus progression of symptomatic ICAS (Model I, Table 3 ). In the multivariable analysis, cilostazol treatment tended to be a predictor for the prevention of ICAS progression (Pϭ0.068). When apoB/AI at 7 months, instead of the nonsignificant RLP-C reduction, was included (Model II, Table 3 ), HDL-C elevation remained significant; cilostazol treatment again, along with the nonsignificant apoB/AI at 7 months, tended to be a predictor for the prevention of ICAS progression (Pϭ0.056). Including all 4 variables-cilostazol treatment, RLP-C reduction, apoB/AI at 7 months, and HDL-C elevation-in another model (online-only Data Supplement Table  III) did not abolish the statistical significance of the HLD-C elevation.
Discussion
This is the first prospective multicenter study to link poststroke changes in lipid profiles with angiographic progression of symptomatic ICAS. In both progression and nonprogression groups, total or LDL-C levels similarly decreased 7 months after acute ischemic infarction in the corresponding vascular territory. In nonprogressors, HDL-C levels increased whereas RLP-C levels decreased; HDL-C elevation but not RLP-C reduction remained statistically significant in multivariable analyses.
We recently reported that patients with acute ischemic stroke with ICAS had a greater apoB/AI ratio than those with no cerebral atherosclerotic stenosis, and they tended to have a higher apoB/AI ratio when compared with those with extracranial atherosclerosis. 3 In the TOSS-2 study, we reported that the cilostazol group had trends toward less progression of symptomatic ICAS compared with the clopidogrel group with significant further reduction in serum levels of apoB and apoB/AI ratio. 12 The present study showed that nonprogressors had higher HDL-C levels and lower apoB/AI ratios than progressors at 7 months. In line with our previous studies, 3, 11 poststroke changes in LDL-C levels as well as LDL-C levels either at baseline or at 7 months did not differ between groups. This suggests that proatherosclerotic LDL-C per se, unlike antiatherosclerotic HDL-C, may exert a relatively minor influence on the poststroke prognosis of symptomatic ICAS. HDL exerts atheroprotective effects by 
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promoting cholesterol efflux from macrophages and inhibiting LDL oxidation, smooth muscle cell migration, and platelet aggregation and reversing endothelial dysfunction. 14 HDL-C has been identified as a strong, independent, inverse predictor of risk of coronary heart disease. 15 We report an independent association between changes in HDL-C levels and progression of symptomatic ICAS. Cilostazol but not clopidogrel appears to have contributed to RLP-C reduction. RLP-C is a well-known risk factor for coronary heart disease 4 -8 and was strongly associated with angiographically verified progression of focal coronary atherosclerosis 16 ; however, roles for RLP-C in cerebrovascular diseases have been rarely investigated. 10, 11 We recently found an association between high RLP-C levels and large artery atherosclerotic stroke. 11 RLP-C may not only be a biomarker, but also a player to affect the pathogenesis of atherosclerosis through several proinflammatory mechanisms [17] [18] [19] [20] such as upregulation of endothelial expression of adhesion molecules and impairment of endothelium-dependent vasomotor function. Impaired vasoreactivity on CT perfusion, MR perfusion, and single photon emission tomography was reported to have a role in predicting future stroke risk in patients with asymptomatic internal carotid artery disease. 21, 22 We failed to observe a significant independent relationship between changes in RLP-C levels and progression of symptomatic ICAS. Studies are required to further investigate the relationship.
In a Japanese study analyzing a heterogeneous group of neurological or asymptomatic patients with ICAS, diabetes and smoking were significant risk factors for progression. 23 This was not supported by our study in patients with stroke with symptomatic ICAS. The WASID trial showed that higher mean blood pressure was associated with increased risk of ischemic stroke and stroke in the territory of the stenotic vessel. 2 In our study, compared with the progression group, the nonprogression group had trends toward having more frequent use of calcium channel blockers and relatively lower diastolic blood pressure levels at 7 months. This may be in line with the results of the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAM-ELOT) trial: compared with the baseline, intravascular ultrasound to measure atheroma volume showed progression of atherosclerosis in the placebo group, a trend toward progression in the enalapril group, and no progression in the amlodipine group. 24 In addition, the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial failed to show any benefit of valsartan in overall cardiac outcome over amlodipine despite lower hospitalizations for heart failure 
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and less frequent new-onset diabetes in the valsartan-treated group; the negative primary outcome results might be explained by the fact that blood pressure decrease in the amlodipine group was more pronounced throughout the trial, particularly during the first 6 months. 25 Internal carotid artery disease is the major cause of stroke in Ͼ70% of the world's population. 1 In addition, the WASID trial showed that symptomatic ICAS had a high clinical recurrence rate for stroke, mostly nonlacunar ischemic stroke in the same vascular territory, which rendered nearly half of the patients disabled. 2, 26 Moreover, the progression of ICAS is known to be associated with clinical stroke recurrence. 26, 27 Thus, our observation of poststroke elevation in HDL-C along with RLP-C reduction and low apoB/AI in prevention of symptomatic ICAS progression may have important clinical implications; poststroke serial measurements of the lipoprotein levels may allow clinicians to identify high-risk patients and stratify preventive therapies. Furthermore, our results could justify more trials to investigate clinical benefits of raising HDL-C as well as improving other lipoprotein profiles 27 such as RLP-C and apoB/AI in patients with symptomatic ICAS.
This study, however, should be interpreted by considering the limitations that subgroup studies are prone to have such as selection bias and small sample sizes. Compared with the nonparticipating subgroup, the study subgroup had different clinical characteristics such as lower baseline National Institutes of Health Stroke Scale scores, less frequent subsequent nonfatal stroke, and more frequent new ischemic MR lesions 
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during the follow-up period. These may have affected the results. In addition, the small number of patients with ICAS progression (nϭ32) versus nonprogression (nϭ198) may indicate that the "dissociation between lipid variables" should be interpreted with caution despite the limited inclusion 28 of 3 or 4 variables with a strict probability value criteria (Ͻ0.05) on univariable analysis and narrow CIs for the adjusted ORs in our multivariable regression models. Despite these limitations, our study further expands the limited current knowledge about pathophysiological roles for HDL-C and RLP-C in the angiographic prognosis of symptomatic ICAS. 
SUPPLEMENTAL MATERIAL
Supplemental Tables
Supplemental Table I Values are presented as frequencies (percentages).
